The estimated Net Worth of William B Stone is at least $1.15 Milión dollars as of 14 August 2017. William Stone owns over 35,000 units of Biodelivery Sciences International stock worth over $889,788 and over the last 20 years William sold BDSI stock worth over $255,843.
William has made over 13 trades of the Biodelivery Sciences International stock since 2004, according to the Form 4 filled with the SEC. Most recently William exercised 35,000 units of BDSI stock worth $195,650 on 14 August 2017.
The largest trade William's ever made was exercising 100,000 units of Biodelivery Sciences International stock on 24 January 2014 worth over $287,000. On average, William trades about 15,133 units every 186 days since 2004. As of 14 August 2017 William still owns at least 159,175 units of Biodelivery Sciences International stock.
You can see the complete history of William Stone stock trades at the bottom of the page.
William's mailing address filed with the SEC is 11120 GEYER DOWNS LANE, , FRONTENAC, MO, 63131.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott a Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: